Review



opp  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress opp
    Opp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-Puromycin/pm42364058-310-1-3
    Average 95 stars, based on 47 article reviews
    opp - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Staining:

    Article Title: In vivo single-cell CRISPR screening for microproteins identifies a critical ribosomal component
    Article Snippet: .. For overall protein synthesis analysis, O-Propargyl-puromycin (OPP, MedChem, MCE-HY-15680) was administered to the different cell lines 1 hour before fixation, followed by staining with Alexa Fluor 647 azide ClickiT reaction (VF 647 Click-iT EdU Universal Cell Proliferation Detection Kit, MedChem, HY-K1084). ..

    Recombinant:

    Article Title: RPS19 and RPL5 haploinsufficient models reveal divergent ribosomal subunit controls of fetal hematopoiesis.
    Article Snippet: The following antibodies were used: CD4-BV605 (Biolegend, #100451, 1:200); CD8a-BV6-5 (Biolegend, #100744, 1:200); Ter119-BV605 (Biolegend, #116239, 1:200); CD45R/B220-BV605 (Biolegend, #103224, 1:200); Ly-6G/Ly-6C-BV605 (Biolegend, # 108440, 1:200); c-Kit-APCeFluor780 (eBioscience, #47-1171-82, 1:200); Sca-1-BV711 (Thermo Scientific, #11-5981-82, 1:200); CD48-AlexaFluor 700 (Biolegend, #103426, 1:200); CD150-BV785 Biolegend, # 115937, 1:200); CD34-PE (BD Biosciences #551387, 1:50); CD34-FITC (BD Biosciences #553733, 1:50); CD16/32-PerCP-Cy5.5 (Thermo Scientific, #45-0161, 1:100); CD71-PE ( eBioscience, #12-0711-83, 1:400); CD44-APC (Biolegend, #100412, 1:200); Ter119-FITC (BD Biosciences, #557915, 1:200); CD45R-APC-Cy7 (BD Biosciences, #552094, 1:200); CD11bAPC-Cy7 (BD Bioscience, #557657, 1:200); Ly6G/Ly6C-APC-Cy7 (BD Biosciences, #557661, 1:200); Annexin V-FITC (Biolegend, #640945, 1:200); GAPDH-HRP (Cell Signaling Technologies, #8884, 1:2,000); p53 (Cell Signaling Technologies, #2524, 1:1,000); Rps19 (Bethyl Labs, #A304-002A, 1:4,000); Rpl5 (Abcam, # ab86863, 1:4,000); AML1 (Cell Signaling Technologies, #4334, 1:10); RPS6 (Cell Signaling Technologies, #2217, 1:4,000); p-RPS6 (Cell Signaling Technologies, #4858, 1:2,000); 4EBP1 (Cell Signaling Technologies, # 9644, 1:1,000); p-4EBP1 (Cell Signaling Technologies, #2855, 1:1,000); p21 (BD Biosciences, #556431, 1:1,000); eEF2 (Cell Signaling Technologies, #2332, 1:1,000); p-eEF2 (Cell Signaling Technologies, #2331, 1:1,000); eIF2α (Cell Signaling Technologies, #5324, 1:4,000); p-eIF2α (Cell Signaling Technologies, #3398, 1:4,000); Actin-β (Cell Signaling Technologies, #4970, 1:4,000); eIF5a (BD Biosciences, #611976, 1:4,000); Hypusine (Creative Biolab, #PABL-202, 1:4,000); PABP1 (Cell Signaling Technologies, #4992, 1:1,000); eIF4E (Cell Signaling Technologies, #2067, 1:1,000); eIF4G (Cell Signaling Technologies, #2469, 1:1,000); eIF4H (Cell Signaling Technologies, # 3469, 1:1,000); AML (Cell Signaling Technologies, #8529, 1:1,000). .. Chemicals, peptides, and recombinant proteins Fetal bovine serum (Cytiva, #SH30071.03); IMDM (Fisher Scientific, #12-440-079); BSA (Fisher Scientific, #BP9703100); PBS (Cytiva, #SH30256.LS); RIPA buffer (Thermo Fisher Scientific, #89900); Agarose (IBI Scientific, #IB70042); Precision Plus Protein Dual Color Standards (BioRad, #1610374); 100 bp DNA Ladder (NEB, #N3231L); Proteinase K (Lamda Biotech, #DB0451-10); O-Propargyl-Puromycin (MedChem Express, #HY-15680); Sucrose (SigmaAldrich, #S9378-1KG); RiboSafe RNase Inhibitor (Bioline, #BIO-65028); Cycloheximide (SigmaAldrich, #C1988-1G); Sodium Chloride (Alfa Aesar, #12314-A3); Magnesium Chloride (SigmaAldrich, #M1028-100ML); DAPI (Sigma-Aldrich, #D9542-10mg); MethoCult M3334 (Stemcell Tech, #M3334); Methocult SF M3436 (Stemcell Tech, #M3436); MethoCult GF M3434 (Stemcell Tech, #M3434); CD117 Microbeads (Miltenyi Biotec, #130-091-224); Anti-Ter-119 MicroBeads (Miltenyi Biotec, #130-049-901); Phosphatase Inhibitor Cocktail (Bio Basic, #PL017); Protease Inhibitor Cocktail (Bimake, #B14002). .. Click-iT Plus EdU Assay Kit (Thermo Scientific, #C10632); Chromium Next GEM Single Cell 3’ Kit (10X Genomics, #1000268); Chromium Next GEM Single Cell Multiome ATAC+Gene Expression Reagent Bundle (10X Genomics, #1000283); Chromium Next GEM Chip G Single Cell Kit (10X Genomics, #1000120); Single Index Kit N, Set A (10X Genomics, #1000212); Dual Index Kit TT, Set A (10X Genomics, #1000215).

    Protease Inhibitor:

    Article Title: RPS19 and RPL5 haploinsufficient models reveal divergent ribosomal subunit controls of fetal hematopoiesis.
    Article Snippet: The following antibodies were used: CD4-BV605 (Biolegend, #100451, 1:200); CD8a-BV6-5 (Biolegend, #100744, 1:200); Ter119-BV605 (Biolegend, #116239, 1:200); CD45R/B220-BV605 (Biolegend, #103224, 1:200); Ly-6G/Ly-6C-BV605 (Biolegend, # 108440, 1:200); c-Kit-APCeFluor780 (eBioscience, #47-1171-82, 1:200); Sca-1-BV711 (Thermo Scientific, #11-5981-82, 1:200); CD48-AlexaFluor 700 (Biolegend, #103426, 1:200); CD150-BV785 Biolegend, # 115937, 1:200); CD34-PE (BD Biosciences #551387, 1:50); CD34-FITC (BD Biosciences #553733, 1:50); CD16/32-PerCP-Cy5.5 (Thermo Scientific, #45-0161, 1:100); CD71-PE ( eBioscience, #12-0711-83, 1:400); CD44-APC (Biolegend, #100412, 1:200); Ter119-FITC (BD Biosciences, #557915, 1:200); CD45R-APC-Cy7 (BD Biosciences, #552094, 1:200); CD11bAPC-Cy7 (BD Bioscience, #557657, 1:200); Ly6G/Ly6C-APC-Cy7 (BD Biosciences, #557661, 1:200); Annexin V-FITC (Biolegend, #640945, 1:200); GAPDH-HRP (Cell Signaling Technologies, #8884, 1:2,000); p53 (Cell Signaling Technologies, #2524, 1:1,000); Rps19 (Bethyl Labs, #A304-002A, 1:4,000); Rpl5 (Abcam, # ab86863, 1:4,000); AML1 (Cell Signaling Technologies, #4334, 1:10); RPS6 (Cell Signaling Technologies, #2217, 1:4,000); p-RPS6 (Cell Signaling Technologies, #4858, 1:2,000); 4EBP1 (Cell Signaling Technologies, # 9644, 1:1,000); p-4EBP1 (Cell Signaling Technologies, #2855, 1:1,000); p21 (BD Biosciences, #556431, 1:1,000); eEF2 (Cell Signaling Technologies, #2332, 1:1,000); p-eEF2 (Cell Signaling Technologies, #2331, 1:1,000); eIF2α (Cell Signaling Technologies, #5324, 1:4,000); p-eIF2α (Cell Signaling Technologies, #3398, 1:4,000); Actin-β (Cell Signaling Technologies, #4970, 1:4,000); eIF5a (BD Biosciences, #611976, 1:4,000); Hypusine (Creative Biolab, #PABL-202, 1:4,000); PABP1 (Cell Signaling Technologies, #4992, 1:1,000); eIF4E (Cell Signaling Technologies, #2067, 1:1,000); eIF4G (Cell Signaling Technologies, #2469, 1:1,000); eIF4H (Cell Signaling Technologies, # 3469, 1:1,000); AML (Cell Signaling Technologies, #8529, 1:1,000). .. Chemicals, peptides, and recombinant proteins Fetal bovine serum (Cytiva, #SH30071.03); IMDM (Fisher Scientific, #12-440-079); BSA (Fisher Scientific, #BP9703100); PBS (Cytiva, #SH30256.LS); RIPA buffer (Thermo Fisher Scientific, #89900); Agarose (IBI Scientific, #IB70042); Precision Plus Protein Dual Color Standards (BioRad, #1610374); 100 bp DNA Ladder (NEB, #N3231L); Proteinase K (Lamda Biotech, #DB0451-10); O-Propargyl-Puromycin (MedChem Express, #HY-15680); Sucrose (SigmaAldrich, #S9378-1KG); RiboSafe RNase Inhibitor (Bioline, #BIO-65028); Cycloheximide (SigmaAldrich, #C1988-1G); Sodium Chloride (Alfa Aesar, #12314-A3); Magnesium Chloride (SigmaAldrich, #M1028-100ML); DAPI (Sigma-Aldrich, #D9542-10mg); MethoCult M3334 (Stemcell Tech, #M3334); Methocult SF M3436 (Stemcell Tech, #M3436); MethoCult GF M3434 (Stemcell Tech, #M3434); CD117 Microbeads (Miltenyi Biotec, #130-091-224); Anti-Ter-119 MicroBeads (Miltenyi Biotec, #130-049-901); Phosphatase Inhibitor Cocktail (Bio Basic, #PL017); Protease Inhibitor Cocktail (Bimake, #B14002). .. Click-iT Plus EdU Assay Kit (Thermo Scientific, #C10632); Chromium Next GEM Single Cell 3’ Kit (10X Genomics, #1000268); Chromium Next GEM Single Cell Multiome ATAC+Gene Expression Reagent Bundle (10X Genomics, #1000283); Chromium Next GEM Chip G Single Cell Kit (10X Genomics, #1000120); Single Index Kit N, Set A (10X Genomics, #1000212); Dual Index Kit TT, Set A (10X Genomics, #1000215).

    Incubation:

    Article Title: Citrate clearance is a major function of aconitase 2 in the canonical TCA cycle
    Article Snippet: .. Cells were changed to media containing 20 μM O-propargyl-puromycin (OP-puro, HY-15680; MedChemExpress) with vehicle or with pyruvate and incubated for 60 min, 30 min, or 15 min. Cycloheximide (Sigma 01810, 10 μg ml− 1) treatment was added to a control well 30 min prior to the start of OPP. .. Cells were collected and stained with Zombie NIR TM Fixable Viability Kit (BioLegend, 423105), followed by fixation with 4% PFA in PBS and permeabilization with 0.25% Triton-X-100.

    Article Title: Citrate clearance is a major function of aconitase 2 in the canonical TCA cycle.
    Article Snippet: .. Cells were changed to media containing 20 μM O-propargyl-puromycin (OP-puro, HY-15680; MedChemExpress) with vehicle or with pyruvate and incubated for 60 min, 30 min, or 15 min. Cycloheximide (Sigma 01810, 10 μg ml− 1) treatment was added to a control well 30 min prior to the start of OPP. .. Cells were collected and stained with Zombie NIRTM Fixable Viability Kit (BioLegend, 423105), followed by fixation with 4% PFA in PBS and permeabilization with 0.25% Triton-X-100.

    Article Title: Differentiation stage-specific use of cap-independent and cap-dependent translation initiation in hematopoiesis
    Article Snippet: LKS were sorted as described above and cultured in StemSpanTMSFEMII (Stem Cell Technologies) supplemented with penicillin (#15140-122, Gibco, 100 IU/mL), streptomycin (#15140-122, Gibco, 100 IU/mL), glutamine (#25030081, Gibco, 2 mM) in addition to mouse recombinant cytokines: SCF (#250-03, Peprotech, 100 ng/mL), IL3 (#213-13, Peprotech, 20 ng/mL), TPO (#315-14, PeproTech, 50 ng/mL), and FLT3-ligand (#250-31L, PeproTech, 100 ng/mL). .. GMPs sorted based on the ratio of IRES/Cap from lineage depleted Translator mouse bone marrow were incubated in a humidified 37°C incubator for 30 minutes in media containing 20 uM O-Propargyl Puromycin (MedChemExpress). .. Cells were stained with the LIVE/DEADTM Fixable Blue stain (ThermoFisher) according to the manufacturer’s protocol followed by fixation using the Fixation/Permeabilization kit (BD Biosciences).

    Control:

    Article Title: Citrate clearance is a major function of aconitase 2 in the canonical TCA cycle
    Article Snippet: .. Cells were changed to media containing 20 μM O-propargyl-puromycin (OP-puro, HY-15680; MedChemExpress) with vehicle or with pyruvate and incubated for 60 min, 30 min, or 15 min. Cycloheximide (Sigma 01810, 10 μg ml− 1) treatment was added to a control well 30 min prior to the start of OPP. .. Cells were collected and stained with Zombie NIR TM Fixable Viability Kit (BioLegend, 423105), followed by fixation with 4% PFA in PBS and permeabilization with 0.25% Triton-X-100.

    Article Title: Citrate clearance is a major function of aconitase 2 in the canonical TCA cycle.
    Article Snippet: .. Cells were changed to media containing 20 μM O-propargyl-puromycin (OP-puro, HY-15680; MedChemExpress) with vehicle or with pyruvate and incubated for 60 min, 30 min, or 15 min. Cycloheximide (Sigma 01810, 10 μg ml− 1) treatment was added to a control well 30 min prior to the start of OPP. .. Cells were collected and stained with Zombie NIRTM Fixable Viability Kit (BioLegend, 423105), followed by fixation with 4% PFA in PBS and permeabilization with 0.25% Triton-X-100.

    Labeling:

    Article Title: Ribosome Molecular Aging Shapes Translation Dynamics
    Article Snippet: .. Nascent polypeptides were labeled by treating cells with 2 μM O-propargyl-puromycin (OPP, MedChemExpress HY-15680). ..



    Similar Products

    opp  (MedChemExpress)
    95
    MedChemExpress opp
    Opp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-Puromycin/pm42364058-310-1-3
    Average 95 stars, based on 1 article reviews
    opp - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    nu  (Jena Bioscience)
    95
    Jena Bioscience nu
    Nu, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-puromycin%2C+Acetate+salt/pmc13016079-56-5-2
    Average 95 stars, based on 1 article reviews
    nu - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    o-propargyl-puromycin  (MedChemExpress)
    95
    MedChemExpress o-propargyl-puromycin
    O Propargyl Puromycin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-Puromycin/custom%40hy-15680%4041616775
    Average 95 stars, based on 1 article reviews
    o-propargyl-puromycin - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    op puro  (MedChemExpress)
    95
    MedChemExpress op puro
    Op Puro, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-Puromycin/pmc13234282-131-2-5
    Average 95 stars, based on 1 article reviews
    op puro - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    o propargyl puromycin  (MedChemExpress)
    95
    MedChemExpress o propargyl puromycin
    O Propargyl Puromycin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-Puromycin/pm41951665-267-50-51
    Average 95 stars, based on 1 article reviews
    o propargyl puromycin - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    nascent polypeptides  (MedChemExpress)
    95
    MedChemExpress nascent polypeptides
    (A) Schematic overview of the experimental strategy used to profile ribosomal RNA modifications in molecular age-dependent translating and collided ribosome subpopulations. (B) Compositional differences of molecularly aged collided 60S and 40S ribosomes (n =2, Fold change (FC) >1.5 fold, p adj < 0.05). (C) Temporal dynamics of Ψ18S-210 in molecular age-dependent 60S ribosome collisions (n = 2). (D) Quantification of newly synthesized <t>polypeptides</t> in Control vs. Ψ18S-210 overexpression cells (n ≥ 848 cells, p < 0.0001, two-tailed Mann-Whitney test). (E) Nuclease-treated polysome analysis of lysates from Control vs. Ψ18S-210 overexpression (OE) cells (F) Quantification of aged and steady-state ribosomes in nuclease-treated sucrose gradients in Control vs. Ψ18S-210 overexpression cells (n = 2). (G) Gene Ontology (Biological Process) terms for nascent polypeptides upregulated by Ψ18S-210 overexpression. (H) Quantification of polybasic stalling reporter readouts in Control vs. Ψ18S-210 overexpression cells (n = 3, p < 0.05, two-tailed Welch’s t test).
    Nascent Polypeptides, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/o+propargyl+puromycin/O-Propargyl-Puromycin/bio_rxiv__64898__2026__03__08__710403-410-0-12
    Average 95 stars, based on 1 article reviews
    nascent polypeptides - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic overview of the experimental strategy used to profile ribosomal RNA modifications in molecular age-dependent translating and collided ribosome subpopulations. (B) Compositional differences of molecularly aged collided 60S and 40S ribosomes (n =2, Fold change (FC) >1.5 fold, p adj < 0.05). (C) Temporal dynamics of Ψ18S-210 in molecular age-dependent 60S ribosome collisions (n = 2). (D) Quantification of newly synthesized polypeptides in Control vs. Ψ18S-210 overexpression cells (n ≥ 848 cells, p < 0.0001, two-tailed Mann-Whitney test). (E) Nuclease-treated polysome analysis of lysates from Control vs. Ψ18S-210 overexpression (OE) cells (F) Quantification of aged and steady-state ribosomes in nuclease-treated sucrose gradients in Control vs. Ψ18S-210 overexpression cells (n = 2). (G) Gene Ontology (Biological Process) terms for nascent polypeptides upregulated by Ψ18S-210 overexpression. (H) Quantification of polybasic stalling reporter readouts in Control vs. Ψ18S-210 overexpression cells (n = 3, p < 0.05, two-tailed Welch’s t test).

    Journal: bioRxiv

    Article Title: Ribosome Molecular Aging Shapes Translation Dynamics

    doi: 10.64898/2026.03.08.710403

    Figure Lengend Snippet: (A) Schematic overview of the experimental strategy used to profile ribosomal RNA modifications in molecular age-dependent translating and collided ribosome subpopulations. (B) Compositional differences of molecularly aged collided 60S and 40S ribosomes (n =2, Fold change (FC) >1.5 fold, p adj < 0.05). (C) Temporal dynamics of Ψ18S-210 in molecular age-dependent 60S ribosome collisions (n = 2). (D) Quantification of newly synthesized polypeptides in Control vs. Ψ18S-210 overexpression cells (n ≥ 848 cells, p < 0.0001, two-tailed Mann-Whitney test). (E) Nuclease-treated polysome analysis of lysates from Control vs. Ψ18S-210 overexpression (OE) cells (F) Quantification of aged and steady-state ribosomes in nuclease-treated sucrose gradients in Control vs. Ψ18S-210 overexpression cells (n = 2). (G) Gene Ontology (Biological Process) terms for nascent polypeptides upregulated by Ψ18S-210 overexpression. (H) Quantification of polybasic stalling reporter readouts in Control vs. Ψ18S-210 overexpression cells (n = 3, p < 0.05, two-tailed Welch’s t test).

    Article Snippet: Nascent polypeptides were labeled by treating cells with 2 μM O-propargyl-puromycin (OPP, MedChemExpress HY-15680).

    Techniques: Synthesized, Control, Over Expression, Two Tailed Test, MANN-WHITNEY

    (A) Compositional differences of molecularly aged translating (monosome) 60S and 40S ribosomes (n = 2, Fold change (FC) >1.5 fold, p adj < 0.05). (B) Schematic overview of the experimental strategy used to profile molecular age-dependent ribosomal RNA modifications in intact, unfractionated lysates. (C) Compositional differences of molecularly-aged 60S- and 40S-associated ribosomes (Fold change (FC) >1.5 fold, p adj < 0.05). (D) Quantitative PCR analysis of SNORA10-28Smut (lacking Ψ28S-4491 modification activity) overexpression relative to control cells (n = 3, p < 0.0001, two-tailed Welch’s t test). (E) BIHIND-qPCR analysis of ribosomal RNA modification overexpression in total RNA (Ψ18S-210: p < 0.05, Ψ28S-4491: p = ns ; two-tailed Welch’s t test). (F) Location of Ψ18S-210 in the structure of the ribosome (PDB: 6QZP). (G) Polysome analysis comparing control and Ψ18S-210 overexpression cells. (H) Growth dynamics of control and Ψ18S-210 overexpression cells (n = 5). (I) Resistance of Ψ18S-210 overexpression (OE) cells to anisomycin treatment relative to control. (J) Volcano plot of IP-MS data of purified nascent polypeptides from Control vs. Ψ18S-210 overexpression (OE) cells (log 2 FC > 1, p adj < 0.05, n = 765 upregulated proteins from n = 3 biological replicates). (K) Median codon frequencies of upregulated nascent polypeptides. (L) Quantitative PCR analysis of SNORA10 expression in human patient fibroblasts of increasing chronological age (n = 3).

    Journal: bioRxiv

    Article Title: Ribosome Molecular Aging Shapes Translation Dynamics

    doi: 10.64898/2026.03.08.710403

    Figure Lengend Snippet: (A) Compositional differences of molecularly aged translating (monosome) 60S and 40S ribosomes (n = 2, Fold change (FC) >1.5 fold, p adj < 0.05). (B) Schematic overview of the experimental strategy used to profile molecular age-dependent ribosomal RNA modifications in intact, unfractionated lysates. (C) Compositional differences of molecularly-aged 60S- and 40S-associated ribosomes (Fold change (FC) >1.5 fold, p adj < 0.05). (D) Quantitative PCR analysis of SNORA10-28Smut (lacking Ψ28S-4491 modification activity) overexpression relative to control cells (n = 3, p < 0.0001, two-tailed Welch’s t test). (E) BIHIND-qPCR analysis of ribosomal RNA modification overexpression in total RNA (Ψ18S-210: p < 0.05, Ψ28S-4491: p = ns ; two-tailed Welch’s t test). (F) Location of Ψ18S-210 in the structure of the ribosome (PDB: 6QZP). (G) Polysome analysis comparing control and Ψ18S-210 overexpression cells. (H) Growth dynamics of control and Ψ18S-210 overexpression cells (n = 5). (I) Resistance of Ψ18S-210 overexpression (OE) cells to anisomycin treatment relative to control. (J) Volcano plot of IP-MS data of purified nascent polypeptides from Control vs. Ψ18S-210 overexpression (OE) cells (log 2 FC > 1, p adj < 0.05, n = 765 upregulated proteins from n = 3 biological replicates). (K) Median codon frequencies of upregulated nascent polypeptides. (L) Quantitative PCR analysis of SNORA10 expression in human patient fibroblasts of increasing chronological age (n = 3).

    Article Snippet: Nascent polypeptides were labeled by treating cells with 2 μM O-propargyl-puromycin (OPP, MedChemExpress HY-15680).

    Techniques: Real-time Polymerase Chain Reaction, Modification, Activity Assay, Over Expression, Control, Two Tailed Test, RNA modification, Protein-Protein interactions, Purification, Expressing

    (A) Schematic of strategy used to quantify PROTAC-mediated degradation of nascent and pre-existing HaloTag fusions. (B) Quantification of nascent and pre-existing HaloTag degradation under Control and PROTAC treatment strategy described in (A) (n ≥ 178 cells, p ≤ 0.01, two-tailed Welch’s t test). (C,D) Correlations between replicates for transcriptome and Ribo-seq experiments under Control and PROTAC treatment. (E) Polysome analysis under Control and PROTAC treatment. (F) Quantification of translation activity under Control and PROTAC treatment by labeling of nascent polypeptides with OP-Puromycin (n ≥ 480 cells, p ≤ 0.0001, two-tailed Welch’s t test). (G) Steady state translation efficiencies for transcripts regulated by PROTAC treatment. (H) Correlation between codon frequency ratios for transcripts regulated by PROTAC treatment and molecularly aged 60S ribosomes. (I) Gene Ontology terms for pausing transcripts (adjusted P < 0.05). (J) Percent of signal and membrane proteins encoded by transcripts regulated by PROTAC treatment according to multiple algorithms. (K) Logo plot of amino acids being decoded at PROTAC-dependent pause sites. (L) Average ribosome occupancy at polybasic regions of different lengths under Control or PROTAC treatment.

    Journal: bioRxiv

    Article Title: Ribosome Molecular Aging Shapes Translation Dynamics

    doi: 10.64898/2026.03.08.710403

    Figure Lengend Snippet: (A) Schematic of strategy used to quantify PROTAC-mediated degradation of nascent and pre-existing HaloTag fusions. (B) Quantification of nascent and pre-existing HaloTag degradation under Control and PROTAC treatment strategy described in (A) (n ≥ 178 cells, p ≤ 0.01, two-tailed Welch’s t test). (C,D) Correlations between replicates for transcriptome and Ribo-seq experiments under Control and PROTAC treatment. (E) Polysome analysis under Control and PROTAC treatment. (F) Quantification of translation activity under Control and PROTAC treatment by labeling of nascent polypeptides with OP-Puromycin (n ≥ 480 cells, p ≤ 0.0001, two-tailed Welch’s t test). (G) Steady state translation efficiencies for transcripts regulated by PROTAC treatment. (H) Correlation between codon frequency ratios for transcripts regulated by PROTAC treatment and molecularly aged 60S ribosomes. (I) Gene Ontology terms for pausing transcripts (adjusted P < 0.05). (J) Percent of signal and membrane proteins encoded by transcripts regulated by PROTAC treatment according to multiple algorithms. (K) Logo plot of amino acids being decoded at PROTAC-dependent pause sites. (L) Average ribosome occupancy at polybasic regions of different lengths under Control or PROTAC treatment.

    Article Snippet: Nascent polypeptides were labeled by treating cells with 2 μM O-propargyl-puromycin (OPP, MedChemExpress HY-15680).

    Techniques: Control, Two Tailed Test, Activity Assay, Labeling, Membrane